


Supplementary Figure S2



**Supplementary Figure S2. Growth of MCF-7 and HBECp53 cells is not sensitive to seribantumab.** MCF-7 (*NRG1* fusion-negative) (A) and untransformed HBECp53 cells (B) were treated with afatinib or seribantumab for 96 h and then viability determined using alamarBlue. (C) Viability data was analyzed by non-linear regression and IC<sub>50</sub> values for inhibition of growth determined using Graphpad Prism 8 software. The 95% confidence interval (CI) is given in brackets. ??? indicates an undefined upper limit. Data for MCF-7 cells represent the mean ± SD of two (seribantumab) or three (afatinib) experiments. For the HBECp53 cells, the data represent the mean ± SD of four replicate determinations in one experiment. (B). RT-PCR showing expression of the *CD74-NRG1* fusion in the HBECp53-*CD74-NRG1* cells.